fda warning letter compounding semaglutide october 2025 Warns on Certain Forms of Compounded FDA warns against compounded GLP-1

Preclinical studies suggest GLP-1 agonism may reduce pro-inflammatory cytokine production, particularly TNF-alpha and IL-6, which are key therapeutic targets in RA

Some (liraglutide, injectable semaglutide, and dulaglutide) have also shown cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease

In patients with AD, an increase in astrocyte-derived circulating exosomes has been observed, which transport proinflammatory cytokines, supporting the idea that reactive astrocytes contribute to inflammation 56

In some cases, the bleeding is slow enough that you cant see it with the naked eye